The Use of Atypical Antipsychotics in Treating a Pediatric Psychiatric Patient

Joshua A. Jogie 1, 2, Kinna Parikh 3, Sheena Mathew 4, Kruthiga Rajasekaran 5, Shaista Arain 6

1. Department of Neonatology, Port-of-Spain General Hospital, Port-of-Spain, TTO 2. Research, The University of the West Indies, St. Augustine Campus, Faculty of Medicine, St. Augustine, TTO 3. Research, Government Medical College, Kottayam, IND 4. Research, Rajah Muthiah Medical College and Hospital, Chidambaram, IND 5. Department of Pediatrics, University of Kentucky Children’s Hospital, Lexington, USA

Corresponding author: Joshua A. Jogie, joshy221196@gmail.com

Abstract

Approaches to enhancing mental health management entail several perspectives and efforts to promote competent treatment. In light of this, we present a case report to describe the nature of events encountered during the management of a psychiatric patient. The paper commences by providing a general introduction and background of the concept of atypical antipsychotics before adding a thesis statement that healthcare providers should be knowledgeable regarding psychopharmacotherapy to effectively design and implement safe patient care. The paper’s method involved the review of a case scenario and discussion of the concepts using evidence-based guidance and perspectives. In the case scenario, a pediatric patient significantly gains weight and develops extrapyramidal effects like dystonias, and erratic, jerky neck movements as a consequence of treatment with olanzapine. The most effective care plan involves stopping the medication, reviewing treatment options, and incorporating physical exercise. Most importantly, the plan encourages achieving an adequate heart rate above 100 beats per minute to maintain sufficient perfusion during exercise. The paper concludes by summarizing the perspectives from the studies reviewed.

Introduction

Quality improvement in psychiatric management often involves several change processes toward establishing a safe and effective healthcare system. Every step in adapting new methods needs to employ the best evidence available as a guiding framework toward change implementation. Daily health interventions and treatments require patient examination and collection of data about their conditions. These approaches invite competent communication ventures and information exchange strategies. Ideally, the current knowledge and evidence require effective communication between healthcare providers and their respective patients [1]. Effective communication and review of treatment approaches may assist in identifying medication side effects and inform the outcome of patient management.

Psychiatric treatments often involve the use of agents that may influence functioning at a higher level. Specifically, therapies involving olanzapine may affect factors related to nutrition, brain motor responses, and tremors and lead to extrapyramidal effects. The drug is a known second-generation antipsychotic that is associated with significant dose-dependent adverse treatment events [2]. Other agents with the same classification include clozapine, quetiapine, risperidone, and aripiprazole [3]. Among the atypical antipsychotics, olanzapine has a far more significant therapeutic effect compared to many other agents in the same group [4,5]. According to Leucht et al., improvement in performance also means that the agent also has far more serious unwanted effects [6].

Against this background, we present a case report to detail the ideal case management of adverse drug events in the treatment of psychiatric disorders. The treatment with olanzapine and other psychiatric medications may contribute to a more stable thought process and elimination of psychosis and suicidal ideations. However, unregulated utilization of the drugs could lead to the progression of extrapyramidal side effects [7]. Therefore, healthcare providers should be knowledgeable regarding the advanced events in psychopharmacotherapy to effectively plan care approaches and protect the patients from harmful experiences.

Case Presentation

Patient X arrived at the emergency department for consultation with an MD after an initial referral by their primary care physician. The main aim of the session was to review their medication before deciding to continue with these drugs. Regarding the chief complaint, the patient mentioned disturbing nervousness and generalized complaints. The accompanying nurse explained that the patient’s symptoms were consistent with general nervousness when in anxiety-inducing situations like attending school and taking...
on doctor’s appointments. The subjective data revealed that the patient experienced jerky erratic tics and a
general raising of shoulders when in a tense situation. These movements were mostly involuntary in
general, occurring without the patient’s awareness. Regarding the history of present illness, the doctor
observed that the patient was able to perform daily activities. The patient’s condition was attributed to the antagonistic
binding of D2 receptors in the brain’s mesolimbic and mesocortical pathways. Toxicity management requires
a therapeutic adjustment of doses based on the reviews provided by the National Center for Biotechnology
[16]. Advanced patient treatment of obesity involves adopting exercise to improve metabolism and
encourage caloric burn. Eventually, the patient’s weight showed a significant reduction in the post-
interventional phase based on the milestone visits and progress documentation. The current evidence,
therefore, recommends dose adjustment and a review of treatment options for patients who experience
olanzapine toxicity.

Conclusions
Psychiatric practice requires adequate and in-depth knowledge of psychopharmacotherapy and related
adverse events to effectively plan the safe treatment of patients. This report highlights the importance of
adopting ethical perspectives in decision-making and prioritizing patients’ wellbeing. We did not mention
the name of the patient in the report. Additionally, the priority in managing the condition was to ascertain
the patient’s wellbeing. Stopping the treatment at once assisted in limiting future and continued
chemotoxicity. During the patient’s medical reconciliation, additional efforts are essential in ensuring the
management of weight gain. The evidence-based perspectives suggest that the patient should engage in low
to moderate-intensity exercise. Additionally, the strategy should ensure that the heart rate constantly
remains above 100 beats per minute to maintain adequate perfusion. Finally, we refrained from revealing
personal details of the patient to the public, adhering to the principles of privacy and patient confidentiality.

Additional Information
Disclosures

On assessing the patient’s objective data, they had an initial weight of 98.43 kg with a height of 154.9
centimeters. With a BMI of 41, the patient belonged to the 99.5th percentile. Other vitals were as follows:
- Blood pressure of 125/95 mmHg, heart rate of 104 beats per minute, temperature of 36.4 °C, and respiration
  rate of 20 breaths per minute. The physical examination involving a head-to-toe assessment did not identify
  any abnormal findings.
- The plan of care required an aggressive approach to stop the adverse drug reactions. The
  management prioritized stopping olanzapine immediately to reduce significant neuronal harm to the
  patient. The plan also involved eliminating excessive carbohydrates and prioritizing vegetables with limited
  protein topping to enrich the taste. Also, the treatment approach advocated for a low to moderate-impact
  physical exercise that would assist in maintaining the heart rate above 100 beats per minute. The specific
  activities included cycling and walking. Eventually, pediatric review and possible change of medication were
deed pivotal for the patient’s treatment continuity.
- The assessment of the patient elicited two critical impressions. The initial impression was that the patient
  was obese and required a nutritional review. The second impression was that the patient was suffering from
  the primary side effects of the drug treatment.

Discussion
Second-generation antipsychotics are serotonin–dopamine antagonists, also identifiable as atypical
antipsychotics [8,9]. Multicenter trials to describe the efficacy and suitability of olanzapine have
documented that the pharmacological agent is a novel treatment approach for managing psychotic
symptoms and schizophrenia [10,11]. According to various studies in the literature, olanzapine use has
drastically decreased over the years because of the associated weight gain and adverse metabolic side effects.
These factors show that the patient’s weight gain was primarily due to unchecked drug consumption. With a
BMI of 41, the patient most definitely had a weakened immune system and high susceptibility to infections.

Regarding the drug’s mechanisms of action, these agents are primarily D2 antagonists, whereas additional
properties may include 5-HT2A antagonism and 5-HT1A agonism [12]. Though more effective compared to
other atypical antipsychotics on average, olanzapine’s side effects may be relatively more severe compared
to those of other second-generation antipsychotics [13,14]. In our case, the patient experienced significant
adverse events. They developed ticks characterized by erratic solid jerky movements in the neck
region. According to D’Souza and Hooten, the exact extrapyramidal symptom spectrum may include
dystonias, akathisia, and parkinsonism [15]. The patient’s condition may be attributed to the antagonistic
binding of D2 receptors in the brain’s mesolimbic and mesocortical pathways. Toxicity management requires
a therapeutic adjustment of doses based on the reviews provided by the National Center for Biotechnology
[16]. Advanced patient treatment of obesity involves adopting exercise to improve metabolism and
encourage caloric burn. Eventually, the patient’s weight showed a significant reduction in the post-
interventional phase based on the milestone visits and progress documentation. The current evidence,
therefore, recommends dose adjustment and a review of treatment options for patients who experience
olanzapine toxicity.
Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Pelletier D, Green-Demers I, Collette R, Heberer M. Modeling the communication-satisfaction relationship in hospital patients. SAGE Open Med. 2019;7(2050312119847924. 10.1177/2050312119847924
2. Thomas K, Saadabadi A. Olanzapine. StatPearls Publishing, Treasure Island, FL; 2022.
3. Kishi T, Ikuta T, Matsunaga S, Matsuda Y, Oya K, Iwata N. Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population. Neuropsychiatr Dis Treat. 2017;13:1281-302. 10.2147/NDDT.S134340
4. Oh S, Lee TY, Kim M, et al. Effectiveness of antipsychotic drugs in schizophrenia: a 10-year retrospective study in a Korean tertiary hospital. NPJ Schizophr. 2020;6:32. 10.1038/s41537-020-00122-3
5. Tilhusen J. Real-world effectiveness of antipsychotics. Acta Psychiatr Scand. 2016;134:371-3. 10.1111/acps.12641
6. Leucht S, Cipriani A, Spinelli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews. Centre for Reviews and Dissemination, University of York, York, UK; 2015. 1:3-7.
7. Citrome L, McEvoy JP, Todtenkopf MS, McDonnell D, Weiden PJ. A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future. Neuropsychiatr Dis Treat. 2019;15:2559-69. 10.2147/NDDT.S209284
8. Chokhawala K, Stevens L. Antipsychotic Medications. StatPearls Publishing, Treasure Island, FL; 2022.
9. Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014:656370. 10.1155/2014/656370
10. Corrao MM, Nelson LA. Olanzapine/samidorphan: a new combination treatment for schizophrenia and bipolar I disorder intended to reduce weight gain. CNS Drugs. 2022;36:605-16. 10.1007/s40263-022-00923-3
11. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37:177-95. 10.2165/00003088-199937030-00001
12. Willner K, Vaxan S, Abdijadad S. Atypical Antipsychotic Agents. StatPearls Publishing, Treasure Island, FL; 2022.
13. Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;3:CD006654. 10.1002/14651858.CD006654.pub2
14. Boyda HN, Procyshyn RM, Tse L, Yuen JW, Honer WG, Barr AM. A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models. PLoS One. 2021;16:e0246211. 10.1371/journal.pone.0246211
15. D’Souza RS, Hooten WM. Extrapyramidal Symptoms. StatPearls Publishing, Treasure Island, FL; 2022.
16. National Center for Biotechnology Information (2022). PubChem Compound Summary for CID 153398745, Olanzapine. (2022). Accessed: July 15, 2022: https://pubchem.ncbi.nlm.nih.gov/compound/Olanzapine.